Given the clinical importance of therapeutic strategies based on immune checkpoint blockade in HCC (32, 33), we then explore the association between the risk score and several immune checkpoints, such as PD1, PDL1, CTLA4, VSIR, and B7H3. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.